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267, 223, and 539 days for OS, respectively). Multivariate 
analysis showed that poor performance status, absence of 
EGFR mutation, and presence of IPF were poor prognostic 
factors for PFS and OS. Disease control rate (DCR) was 
significantly lower in ILD and IPF patients than in non-ILD 
patients regardless of the presence of EGFR mutation (67 
or 53 vs. 85 %, respectively). The incidence of AEs of ILD 
was significantly higher during chemotherapy with doc-
etaxel-containing regimens (seven of 38; 18.4 %).
Conclusions Both IPF and ILD were associated with lower 
EGFR positivity, lower DCR, and shorter PFS and OS in 
advanced NSCLC patients.
Keywords Interstitial lung disease · Chemotherapy · 
Docetaxel · Acute exacerbation · Epidermal growth factor 
receptor · Advanced lung cancer
Introduction
Interstitial lung diseases (ILDs), also called interstitial 
lung abnormalities (ILA) or interstitial pneumonia (IP), are 
characterized by diffuse pulmonary interstitial abnormali-
ties that often lead to fibrosis (Borchers et al. 2011). Recent 
evidence has shown that preexisting ILD is associated with 
shorter survival in patients with advanced non-small cell 
lung cancer (NSCLC) (Kinoshita et al. 2012; Nishino et al. 
2015). In a study of NSCLC patients receiving chemo-
therapy, 22 of whom had idiopathic interstitial pneumonia 
(IIP), IIP was found to be a significantly unfavorable factor 
for progression-free survival (PFS) (95.0 vs. 199.5 days) 
and overall survival (OS) (163.0 vs. 400.0 days) (Kinosh-
ita et al. 2012). In another study, NSCLC patients with 
high ILA scores according to computed tomography (CT) 
Abstract 
Purpose The clinical features of patients with advanced 
non-small cell lung cancer (NSCLC) and interstitial lung 
disease (ILD) have not fully been elucidated. This study 
aimed to investigate the clinical features of these patients, 
particularly with idiopathic pulmonary fibrosis (IPF).
Methods Data on 218 patients with pathologically con-
firmed diagnoses of NSCLC who had been treated with 
chemotherapy and/or molecular targeted therapy were ret-
rospectively analyzed for progression-free survival (PFS), 
overall survival (OS), responses to first-line therapy, and 
incidence of acute exacerbations (AEs).
Results Fifty-three of the 218 patients were diagnosed with 
ILD, and 34 of them with IPF. The frequency of epidermal 
growth factor receptor (EGFR) mutation was significantly 
lower in ILD and IPF patients than in non-ILD patients 
(2 or 0 vs. 32 %, respectively). Median PFS and OS were 
significantly shorter in both ILD and IPF patients than 
in non-ILD patients (118, 92, and 196 days for PFS, and 
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findings had shorter OS (n = 17, 7.2 months) than those 
without ILA (n = 103, 14.8 months) (Nishino et al. 2015).
Idiopathic pulmonary fibrosis (IPF), the commonest type 
of ILD (Borchers et al. 2011), is defined as a specific form 
of chronic, progressive fibrosing IP of unknown cause, 
occurring primarily in older adults, limited to the lungs, 
and associated with the histopathologic and/or radiologic 
patterns of usual interstitial pneumonia (UIP) (Raghu et al. 
2011). IPF was recently reported to be a poor prognostic 
factor in patients with surgically treated NSCLC (Goto 
et al. 2014; Lee et al. 2014). Only one study has focused 
on the efficacy of chemotherapy in advanced NSCLC 
with IPF (Watanabe et al. 2013). The authors reported that 
21 patients with IPF had an overall response rate (RR), 
PFS, and OS of 42.9 %, 5.4, and 11.4 months, respec-
tively (Watanabe et al. 2013). No published studies have 
compared the survival of IPF and non-ILD patients with 
advanced NSCLC.
Because there is limited clinical information regarding 
advanced NSCLC patients with IPF, we retrospectively 
compared the efficacy of chemotherapy and survival in 
NSCLC patients with ILD or IPF with that in patients with-
out ILD. In addition, we investigated the incidence, risk 




This study was approved by the Institutional Review Board 
of Kagawa University. Patients with pathologically con-
firmed advanced (stage IIIB or IV) NSCLC who presented 
to the Department of Internal Medicine, Kagawa University 
Hospital, between January 2007 and July 2015 were retro-
spectively identified, and relevant clinical and laboratory 
data were collected from their medical records. Patients 
who (1) had received definitive thoracic irradiation (usu-
ally more than 60 Gy), (2) had another concomitant active 
malignancy, or (3) had received only best supportive care 
were excluded, whereas those treated with chemotherapy 
and/or molecular targeted therapy such as tyrosine kinase 
inhibitors (TKIs) for epidermal growth factor receptor 
(EGFR) were included.
Classification of ILD and diagnosis of IPF and AE
The classification of ILD was made in accordance with 
the ATS/ERS/Japanese Respiratory Society/Latin Ameri-
can Thoracic Association Statement (Raghu et al. 2011). 
UIP pattern was defined as having all the following four 
features: (1) subpleural, basal predominance; (2) reticular 
abnormality; (3) honeycombing with or without traction 
bronchiectasis; and (4) absence of features listed as incon-
sistent with UIP pattern (Raghu et al. 2011). If honeycomb-
ing was absent, but other features met the criteria for UIP, 
the case was classified as possible UIP pattern (Raghu et al. 
2011).
The diagnosis of IPF was based on the following crite-
ria: (1) UIP pattern on high-resolution computed tomogra-
phy and (2) exclusion of other known causes of interstitial 
lung diseases (Raghu et al. 2011). No patients in this study 
underwent surgical lung biopsy to diagnose IPF.
According to the sequential reading method, a board-
certificated pulmonologist (N.K.) and a board-certificated 
radiologist (M.M.) independently reviewed all subjects’ 
CT scans and classified them into four categories: UIP 
pattern, possible UIP pattern, inconsistent with UIP pat-
tern, and without ILD. Accordance of their classifica-
tions was considered a definite diagnosis. When their 
classifications differed, two other board-certificated pul-
monologists (T.T. and A.T.) carefully reviewed the scans 
independently; the diagnosis was considered definite 
if the classifications of three of the four readers were in 
accord. When two readers agreed on one classification 
and the other two another, the case was discussed until 
all four readers agreed on a diagnosis (this procedure was 
required in two cases).
Diagnoses of AEs of ILD were made in accordance with 
criteria detailed in previous studies as follows: (1) worsen-
ing of dyspnea within 30 days; (2) new radiologic bilateral 
ground-glass abnormality and/or consolidation superim-
posed on a background of reticular shadows or honeycomb-
ing; (3) no evidence of pulmonary infection; and (4) exclu-
sion of alternative causes, including left heart failure, 
pulmonary embolism, and acute lung injury of identifiable 
cause (Collard et al. 2007; Kinoshita et al. 2012).
Statistical analysis
PFS was defined as the time between the start of chemo-
therapy or molecular targeted therapy and diagnosis of 
disease progression or death. OS was defined as the time 
between the date of diagnosis and date of death from any 
cause. PFS and OS curves were constructed by the Kaplan–
Meier method, and differences in survivals compared using 
the log-rank test. Fisher’s exact test and Student’s t test 
were used to analyze patient characteristics and the signifi-
cance of the association of AE with ILD or IPF. Laboratory 
and pulmonary function data are presented as mean ± SD. 
All statistical analyses were performed using Ekuseru-
Toukei 2015 (Social Survey Research Information, Tokyo, 
Japan).




In all, 285 patients with pathologically confirmed advanced 
(stage IIIB or IV) NSCLC were identified for this study, 
29 of whom had received definitive thoracic irradiation, 
four had another concomitant active malignancy (malig-
nant lymphoma, renal, gastric, or colon cancer), and 34 
had received only best supportive care. Thus, 218 patients 
were included in this study. Samples were obtained by 
transbronchial biopsy (131 cases), percutaneous biopsy (71 
cases including 31 pleural effusions), surgical resection (9 
cases), and others such as biopsy at different departments 
(7 cases).
Classification of ILD and diagnosis of IPF
Relevant characteristics of patients treated with chemo-
therapy and/or molecular targeted therapy are shown in 
Table 1. ILD was identified in 53/218 patients (24.3 %): 35 
were diagnosed as having UIP, 15 possible UIP, and three 
inconsistent with UIP. One patient had dermatomyositis-
related UIP pattern, and the remaining 34 with UIP pattern 
were diagnosed as having IPF (15.6 % of 218 patients).
Patients with ILD were significantly older than those 
without ILD and more often male and smokers (Table 1). 
The frequency of adenocarcinoma was lower, and that of 
squamous cell carcinoma was higher in patients with ILD 
than in those without it (40 vs. 78 % for adenocarcinoma, 
and 36 and 13 % for squamous cell carcinoma, respec-
tively). EGFR mutation was detected in 53/112 non-ILD 
patients (32 %) and in only one of 53 ILD patients (2 %). 
These differences were more extreme in patients with IPF, 
all of whom were male smokers. Adenocarcinoma and 
squamous cell carcinoma histology each comprised 35 % 
of cases, and no EGFR mutations were detected. Average 
of percent vital capacity (%VC) is significantly lower in 
IPF than in non-ILD patients (76.4 % vs 89.1 %, respec-
tively, P = 0.0115, data not shown).
Table 1  Characteristics of patients treated with chemotherapy and/or molecular targeted therapy
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, PS performance status, EGFR epidermal growth factor receptor
Non-ILD (n = 165) ILD
All ILD (n = 53) P (vs. non-ILD) IPF (n = 34) P (vs. non-ILD)
Age, years (range) 66 (30–91) 71 (57–86) 0.00027 70 (57–86) 0.0053
Sex
 Male 95 (58 %) 51 (96 %) <0.0001 34 (100 %) <0.0001
 Female 70 (42 %) 2 (4 %) 0 (0 %)
Smoking status
 Never 56 (34 %) 2 (4 %) <0.0001 0 (0 %) <0.0001
 Ever 109 (66 %) 51 (96 %) 34 (100 %)
 Pack-year, average 52 34 67
PS
 0–1 134 (81 %) 43 (81 %) 1.0000 27 (79 %) 0.8123
 2–4 31 (19 %) 10 (19 %) 7 (21 %)
Histology
 Adeno 129 (78 %) 21 (40 %) <0.0001 12 (35 %) <0.0001
 Squamous 22 (13 %) 19 (36 %) 0.0005 12 (35 %) 0.0046
 Adenosquamous 1 2 2
 Large 1 2 1
 Non-small 12 9 7
Stage
 IIIB 14 6 0.5854 3 1.0000
 IV 151 47 31
EGFR mutation
 Yes 53 (32 %) 1 (2 %) <0.0001 0 (0 %) <0.0001
 No 112 (68 %) 52 (98 %) 34 (100 %)
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Responses to chemotherapy and/or molecular targeted 
therapy
First-line therapy was cytotoxic chemotherapy in 179/218 
patients and EGFR-TKI in the remaining 39 (Table 2). Fewer 
than three cycles of first-line chemotherapy were received by 
72 and 82 % of ILD and IPF patients, respectively, both per-
centages being significantly higher than for non-ILD patients 
(37 %, P < 0.0001). RR evaluated by RECIST was 55, 37, 
and 31 % for non-ILD, ILD, and IPF patients, respectively. 
Disease control rate (DCR) was 87, 71, and 53 % in non-
ILD, ILD, and IPF patients, respectively. RR and DCR were 
significantly lower in ILD and IPF patients than in non-ILD 
patients. When patients with EGFR mutation were excluded 
(n = 54), RR was 44, 35, and 31 % for non-ILD, ILD, and 
IPF patients, respectively. DCR was 85, 67, and 53 % for 
non-ILD, ILD, and IPF patients, respectively. Although RR 
was not significantly different in subjects with EGFR wild 
type (WT), the DCR was significantly lower in ILD and IPF 
than in non-ILD patients.
Shorter PFS and OS in patients with ILD or IPF
Kaplan–Meier survival curves for NSCLC patients who 
received chemotherapy and/or molecular targeted therapy 
showed a significantly shorter median PFS (Fig. 1a, 118 vs. 
196 days, P = 0.0007) and OS (Fig. 1b, 267 vs 539 days, 
P = 0.001) in ILD than in non-ILD patients. In patients 
with IPF, median PFS (92 days, P < 0.0001) and OS 
(223 days, P = 0.0002) were even shorter (Fig. 2).
Univariate analysis by the log-rank test identified that 
male sex, smoking history, poor performance status (PS), 
non-adenocarcinoma histology, and EGFR-WT were asso-
ciated with poor PFS and/or OS (Table 3). Multivariate 
analysis by Cox proportional hazards model showed that 
poor PS, absence of EGFR mutation, and presence of IPF 
were identified as poor prognostic factors for PFS and OS.
Because EGFR mutation status is associated with sur-
vival and differs between non-ILD and ILD/IPF patients, 
PFS and OS were assessed in these patients. Interestingly, 
PFS and OS were still shorter in ILD and IPF patients with 
EGFR-WT. Median PFS was 180, 118, and 92 days for 
non-ILD, ILD, and IPF patients, respectively (P = 0.0301 
for non-ILD vs. ILD and P = 0.0018 for non-ILD vs. IPF). 
Median OS was 458, 258, and 223 days for non-ILD, ILD, 
and IPF patients, respectively (P = 0.0202 for non-ILD vs. 
ILD and P = 0.0126 for non-ILD vs. IPF).
Factors associated with AEs of ILD
AEs were observed in 10/53 patients (18.9 %) with ILD 
(Table 5). Limited to patients with IPF, AEs developed 
Table 2  Response to first-line chemotherapy/molecular targeted therapy
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, CR complete response, PR partial response, SD stable disease, PD progressive 
disease, NA not assessed
Non-ILD (n = 165) ILD
All ILD (n = 53) P (vs. non-ILD) IPF (n = 34) P (vs. non-ILD)
Number of cycles of chemotherapy, average (range) 5 (1–24) 4 (1–34) 0.1121 3 (1–12) 0.0014
Number of patients who received fewer than three 
cycles (%)
61 (37 %) 38 (72 %) <0.0001 28 (82 %) <0.0001
All patients
 CR 4 0 0
 PR 86 19 10
 SD 51 17 7
 PD 22 15 15
 NA 2 2 2
 Response rate 55 % 37 % 0.0363 31 % 0.0193
 Disease control rate 87 % 71 % 0.0180 53 % 0.0001
Patients without EGFR mutation
 CR 2 0 0
 PR 46 18 10
 SD 46 17 7
 PD 16 15 15
 NA 2 2 2
 Response rate 44 % 35 % 0.3910 31 % 0.2278
 Disease control rate 85 % 67 % 0.0304 53 % 0.0004
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in 6/34 patients (17.6 %). No factors associated with the 
occurrence of AE were identified. However, the incidence 
of AEs differed between chemotherapeutic regimens 
(Table 4). The number of regimen types received by each 
patient was counted as shown by the following exam-
ple: carboplatin plus pemetrexed plus bevacizumab fol-
lowed by pemetrexed plus bevacizumab was classified as 
one regimen type. The same regimen administered to two 
patients was counted as two regimens. In all, 96 regimens 
were administered to 53 patients with ILD. When they con-
tained docetaxel, the incidence of AEs was 18.4 % (7/38 
regimens), which is significantly higher than for regimens 
without docetaxel (5.2 %, P = 0.0472). In IPF patients, 
docetaxel-containing regimens resulted in a trend toward 
higher incidence of AEs (5/24 patients; 20.8 %), whereas 
only 1/29 regimens (3.4 %) without docetaxel led to AEs 
(P = 0.0802); this difference is not statistically significant. 
No ILD patients received EGFR-TKI.
Median PFS in patients with and without AE was 118 
versus 124 days (P = 0.4244), and median OS was 142 
versus 284 days (P = 0.1099). Although these differences 
are not statistically significant, 6/10 patients died quickly 
after the onset of their AEs (Table 6). All patients who 
developed AEs were treated with corticosteroids, including 
methylprednisolone pulse therapy, and received no further 
chemotherapy.
The reasons for discontinuation of first-line chemo-
therapy within three cycles were investigated (Table 7). 
Interestingly, discontinuation because of adverse events 
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Fig. 1  Kaplan–Meier curves of (a) progression-free survival and (b) 
overall survival in advanced NSCLC patients with interstitial lung 
disease (ILD) who received chemotherapy and/or molecular targeted 
therapy
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Fig. 2  Kaplan–Meier curves of (a) progression-free survival and (b) 
overall survival in advanced NSCLC patients with idiopathic pulmo-
nary fibrosis (IPF) who received chemotherapy and/or molecular tar-
geted therapy
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non-ILD patients (42, 46, and 21 %, respectively). Impor-
tantly, 6/16 adverse events that resulted in discontinuation 
of chemotherapy were AEs in ILD patients. In IPF patients, 
AEs comprise 6/13 adverse events.
Discussion
In the present study, we demonstrated that (1) characteris-
tics of ILD/IPF patients differed significantly from those of 
non-ILD patients; in particular, no IPF patients had EGFR 
mutation-positive tumors; (2) the presence of either IPF or 
ILD was associated with shorter PFS and OS in patients 
with advanced NSCLC who received chemotherapy; (3) 
DCR was significantly lower in ILD and IPF patients than 
in non-ILD patients, even those with EGFR-WT; and (4) 
AEs of ILD occurred more frequently after docetaxel-con-
taining regimens than after other regimens.
The present study clearly demonstrated several dif-
ferences in the characteristics of non-ILD and ILD/IPF 
patients. Most ILD and all 34 IPF patients were male 
smokers and had EGFR-WT. It is particularly interesting 
that no IPF patients had EGFR mutation-positive cancers, 
which has been shown for the first time although a previous 
study has reported a correlation between preexisting ILD 
and EGFR-WT adenocarcinoma (Fujimoto et al. 2013). In 
that study, only one of 31 ILD patients with lung adeno-
carcinoma had an EGFR mutation; this patient had a non-
UIP radiographic pattern (Fujimoto et al. 2013). The cur-
rent study extended this finding in that our one ILD patient 
with EGFR mutation also had a radiologic pattern incon-
sistent with UIP pattern. The frequency of squamous cell 
Table 3  Risk factors associated with PFS and OS
PFS progression-free survival, OS overall survival, HR hazard ratio, PS performance status, EGFR epidermal growth factor receptor, ILD inter-






Multivariate analysis Median (days) Univariate 
analysis
Multivariate analysis









 Female 72 228 0.0403 1.05 (0.67–1.67) 0.8247 638 0.0030 0.81 (0.48–1.36) 0.4219
 Male 146 149 398
Smoking status
 Never 58 237 0.0405 0.84 (0.52–1.33) 0.4536 610 0.0242 0.95 (0.57–1.61) 0.8595
 Ever 160 149 430
PS
 0–1 178 202 <0.0001 0.35 (0.24–0.52) <0.0001 538 <0.0001 0.24 (0.16–0.36) <0.0001
 2–4 40 79 139
Histology
 Adeno 150 190 0.0430 1.02 (0.71–1.47) 0.8954 539 0.0009 1.00 (0.67–1.49) 0.9929
 Others 68 150 283
Stage
 IIIB 20 185 0.7203 0.78 (0.47–1.28) 0.3246 495 0.9407 0.90 (0.52–1.56) 0.7136
 IV 198 180 471
EGFR mutation
 Yes 54 304 0.0003 0.55 (0.37–0.82) 0.0037 771 0.0001 0.51 (0.33–0.81) 0.0042
 No 164 149 360
ILD
 IPF 34 92 0.00002 1.98 (1.26–3.11) 0.0030 223 0.0002 1.74 (1.03–2.92) 0.0373
 Non-ILD 165 196 539
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carcinoma was higher in IPF than in non-ILD patients (35 
vs. 13 %). In ILD patients, most tumors reportedly develop 
in the area affected by ILD (Fujimoto et al. 2013; Kanaji 
et al. 2015). The current study provides evidence that car-
cinogenesis in IPF differs from that in non-ILD patients in 
that it is not associated with EGFR mutation.
Table 4  Associations between chemotherapeutic regimens and acute exacerbation of ILD and IPF
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, AE acute exacerbation
ILD IPF
n AE (−) AE (+) Incidence (%) P value n AE (−) AE (+) Incidence (%) P value
Docetaxel
 Containing 38 31 7 18.4 0.0472 24 19 5 20.8 0.0802
 Not containing 58 55 3 5.2 29 28 1 3.4
Pemetrexed
 Containing 15 13 2 13.3 0.6531 8 7 1 12.5 1.0000
 Not containing 81 73 8 9.9 45 40 5 11.1
Paclitaxel/nab-paclitaxel
 Containing 12 12 0 0.0 0.3533 5 5 0 0.0 1.0000
 Not containing 84 74 10 11.9 48 42 6 12.5
Table 5  Patient characteristics associated with acute exacerbations of ILD and IPF
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, AE acute exacerbation, PS performance status, EGFR epidermal growth factor 
receptor, LDH lactate dehydrogenase, VC vital capacity, FVC forced vital capacity
ILD IPF
AE (−) (n = 43) AE (+) (n = 10) P value AE (−) (n = 28) AE (+) (n = 6) P value
Age
 Older (≥75 years) 13 5 0.2792 9 3 0.6410
 Younger (<75 years) 30 5 19 3
Sex
 Female 1 1 0.3447 0 0 1.0000
 Male 42 9 28 6
Smoking status
 Never 1 1 0.3447 0 0 1.0000
 Ever 42 9 28 6
PS
 0–1 36 7 0.3761 23 4 0.5798
 2–4 7 3 5 2
Histology
 Adeno 19 5 0.7411 10 2 1.0000
 Others 24 5 18 4
Stage
 IIIB 5 1 1.0000 3 0 1.0000
 IV 38 9 25 6
EGFR mutation
 Yes 0 1 0.1887 0 0 1.0000
 No 43 9 28 6
LDH 283 ± 127 314 ± 126 0.5208 277 ± 114 340 ± 143 0.3829
KL-6 808 ± 608 688 ± 372 0.5435 865 ± 664 807 ± 460 0.8625
%VC 81.8 ± 19.8 84.4 ± 18.5 0.7426 78.0 ± 18.0 71.6 ± 13.8 0.4691
%FVC 79.7 ± 20.2 80.6 ± 18.7 0.9085 78.1 ± 18.3 67.2 ± 13.8 0.2263
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Consistent with previous studies (Borchers et al. 2011; 
Watanabe et al. 2013), IPF was the commonest type of ILD 
(34/53 patients; 64 %). Even in patients with EGFR-WT, 
PFS and OS were significantly shorter in IPF than in non-
ILD patients. These findings indicate that the presence of 
IPF predicts an extremely poor prognosis in patients with 
advanced NSCLC. Lower %VC (<80 %) was also asso-
ciated with shorter survivals (120 vs 196 days for PFS, 
P = 0.0043, and 266 vs 538 days for OS, P = 0.0023, 
respectively, data not shown). Shorter survival in lower 
%VC has been reported in patients with NSCLC and ILD 
who underwent surgical resection (Sato et al. 2015).
Another important finding of the current study is regard-
ing response to chemotherapy/molecular targeted therapy. 
RR and DCR in ILD/IPF patients were lower than that in 
non-ILD patients. EGFR mutation was not identified in any 
of the 34 IPF patients, whereas 32 % of non-ILD patients 
harbored EGFR mutations. Because the response to EGFR-
TKI is much better in tumors with EGFR mutation than in 
EGFR-WT, the lower RR in IPF patients may be associated 
with the absence of EGFR mutations. Indeed, the differ-
ence in RR was not significant for EGFR-WT patients; 
interestingly, however, a difference in DCR was observed, 
even in patients without EGFR mutations.
There are several possible mechanisms that could 
explain the lower DCR and shorter survival of ILD/IPF 
patients. First, ILD/IPF patients may experience adverse 
events more frequently. Indeed, adverse events, including 
AEs, and PD were the main reasons for discontinuing first-
line therapy within three cycles in patients with ILD/IPF, 
suggesting that AEs of ILD/IPF may have made an impor-
tant contribution to the lower DCR and shorter survival. 
Consistent with this, coexisting ILD is reportedly associ-
ated with a high risk of developing chemotherapy-induced 
ILD (Sakurada et al. 2015). Chemotherapeutic strategies 
that do not induce AEs or deterioration of ILD are needed.
Second, an altered drug delivery system may lead to the 
lower response and shorter survival of ILD/IPF patients. 
Histological features of the UIP pattern include marked 
pulmonary fibrosis and architectural distortion (Raghu 
Table 6  Outcomes of ten patients with acute exacerbations of ILD
ILD interstitial lung disease, UIP usual interstitial pneumonia, IPF idiopathic pulmonary fibrosis, AE acute exacerbation




Onset of AE (days from 
chemotherapy)
Outcome of AE Survival (days from 
onset of AE)
1 Possible UIP Pemetrexed (second) 1 13 Died 16
2 Inconsistent with UIP S-1 (third) 1 26 Died 2
3 Possible UIP Carboplatin and doc-
etaxel (first)
5 150 Died 36
4 IPF Carboplatin and doc-
etaxel (first)
1 15 Died 12
5 IPF Carboplatin and pem-
etrexed (first)
2 41 Recovered 81
6 IPF Carboplatin and doc-
etaxel (first)
3 22 Died 4
7 IPF Docetaxel (first) 2 52 Recovered 80
8 IPF Docetaxel (first) 2 46 Died 4
9 Possible UIP Docetaxel (second) 2 28 Recovered 385
10 IPF Docetaxel (first) 1 18 Recovered 108
Table 7  Reasons for discontinuation of first-line chemotherapy within three cycles
Note Because numbers are shown as events, the total number may exceed patient numbers and the total percentage will exceed 100 %
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, PD progressive disease, PS performance status
Non-ILD (n = 61) ILD
All ILD (n = 38) P (vs. non-ILD) IPF (n = 28) P (vs. non-ILD)
PD 21 (34 %) 14 (37 %) 0.8316 13 (46 %) 0.3490
Deterioration in PS 12 (20 %) 7 (18 %) 1.0000 5 (18 %) 1.0000
Adverse events 13 (21 %) 16 (42 %) 0.0403 13 (46 %) 0.0234
Acute exacerbation – 6 6
Others 16 (26 %) 4 (11 %) 0.0735 1 (4 %) 0.0100
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et al. 2011). Alveolar epithelial cell damage, dysregulation 
of fibroblasts, and vascular injury and aberrant angiogen-
esis related to vascular remodeling are key elements of lung 
fibrosis (Selman and Pardo 2006; Wémeau-Stervinou et al. 
2012). Destruction of normal vasculature would logically 
reduce the local delivery of chemotherapeutic agents to a 
tumor.
Third, acquired drug resistance may result in lower DCR 
and shorter survival in ILD/IPF patients. In this regard, 
transforming growth factor (TGF)-β may have a role. Many 
cytokines and growth factors, including TGF-β, are report-
edly associated with the development of ILD/IPF (Das 
et al. 2014; Kanaji et al. 2014). TGF-β concentrations are 
higher in bronchoalveolar lavage fluid obtained from IPF 
than from control patients (Khalil et al. 2001). TGF-β is 
reportedly associated with chemoresistance in colon cancer 
(Li et al. 2015). Additionally, TGF-β is a major regulator of 
epithelial–mesenchymal transition in the alveolar epithelia 
(Kasai et al. 2005; Miyazono 2009). In epithelial–mesen-
chymal transition, cancer cells seemingly acquire chem-
oresistance in lung and other types of cancers (Jiang et al. 
2015; Li et al. 2014; Wang et al. 2015). Thus, increased 
TGF-β in the lung’s microenvironment may be a causa-
tive factor for lower DCR and shorter survival in NSCLC 
patients with ILD/IPF.
Regarding AEs of ILD, several studies have reported 
docetaxel-induced AE (Tamiya et al. 2012; Watanabe et al. 
2015). In 35 patients with NSCLC and IP treated with doc-
etaxel monotherapy, the incidence of AEs of IP was 14.3 % 
(5/35 patients). Three of the five patients who developed 
AEs of IP died (Watanabe et al. 2015). In another study, 
deterioration of ILD was observed in 7/27 patients (25.9 %) 
with NSCLC and preexisting ILD (Tamiya et al. 2012). In 
contrast, 6/309 patients (1.9 %) without preexisting ILD 
reportedly developed it after receiving docetaxel (Tamiya 
et al. 2012). In the current study, there was also a higher 
incidence of AEs of ILD/IPF after docetaxel-containing 
chemotherapy. Of note, AEs also occurred in 3/15 patients 
with radiographic possible UIP pattern (20 %). Several 
studies have reported that possible UIP pattern often cor-
responds with pathologically confirmed UIP (Sumikawa 
et al. 2014; Raghu et al. 2014). Radiographic possible UIP 
pattern should be considered clinically similar to UIP when 
choosing treatment strategies for patients with advanced 
NSCLC. Administration schedule also affects the incidence 
of AEs (higher incidence in a weekly than in triweekly 
administration) (Chen et al. 2006). Anti-microtubule activ-
ity by taxanes itself seems not to be related in the devel-
opment of AE because the incidence of AE in paclitaxel is 
different from that in docetaxel. Thus, factors other than 
anticancer activity might be associated with docetaxel-
related AE although an actual mechanism has never been 
reported.
No optimal chemotherapeutic regimen for patients with 
advanced NSCLC and underlying ILD has been established 
(Watanabe et al. 2015). A combination of carboplatin and 
weekly paclitaxel may be a treatment option for NSCLC 
with ILD (Minegishi et al. 2011). Eighteen patients with 
ILD, including six with IPF, treated with carboplatin and 
paclitaxel achieved PFS and median survival time of 5.3 
and 10.6 months, respectively (Minegishi et al. 2011). Only 
one patient (5.6 %) with IPF developed an AE (after four 
cycles of chemotherapy). However, in another study 4/15 
patients with NSCLC and ILD who received carboplatin 
and paclitaxel developed grade 3 or higher pneumonitis 
(27 %) (Shukuya et al. 2010); this high incidence cannot 
be ignored. In a phase III trial, administration of albumin-
bound paclitaxel (nab-paclitaxel) as first-line treatment in 
patients with advanced NSCLC without ILD was effec-
tive and resulted in a higher RR than conventional solvent-
based paclitaxel (Socinski et al. 2012). Currently, several 
clinical trials are assessing a combination of carboplatin 
and nab-paclitaxel for advanced NSCLC with ILD.
Nintedanib is a multiple tyrosine kinase inhibitor, and 
INPULSIS-2 trial demonstrated that nintedanib reduced 
the time to first AE compared with placebo (Richeldi et al. 
2014). In addition, a combination of docetaxel and nint-
edanib showed a benefit on OS over docetaxel monother-
apy as second-line treatment (Reck et al. 2014). The addi-
tion of nintedanib to cytotoxic agents such as docetaxel 
may be more effective with fewer adverse events.
The prevalence of ILD and IPF in this study was 24.3 
and 15.6 %, respectively, and seems to be higher than in 
previous reports (7.3–14 %) (Kinoshita et al. 2012; Nishino 
et al. 2015). However, among 387 patients who received 
surgical resection, 65 (16.8 %) were confirmed as under-
lying IPF (Goto et al. 2014). Location of the institution 
would greatly influence the prevalence of ILD and IPF as 
well as smoking status.
The limitations of this study are as follows. First, this 
was a retrospective, single-center study; a prospective, 
multicenter large study including both non-ILD and ILD 
patients is desirable to further investigate clinical differ-
ences in response to chemotherapy. Second, all patients 
were Japanese: Some studies have shown ethnic differences 
in incidence of drug-induced lung injury and other pulmo-
nary diseases (Azuma et al. 2008; Natsuizaka et al. 2014). 
The incidence of AEs of ILD/IPF may vary between differ-
ent ethnicities.
Conclusions
This study showed, for the first time, that patients with 
advanced NSCLC and IPF have shorter PFS and OS and 
lower DCR than patients without ILD. Docetaxel-containing 
1864 J Cancer Res Clin Oncol (2016) 142:1855–1865
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chemotherapeutic regimens were more frequently associ-
ated with AEs than other regimens. Because survival after 
onset of AEs is usually short, more effective therapeutic 
strategies that do not induce AEs should be identified.
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